Evercore ISI Raises its Price Target on Twist Bioscience (TWST)

Twist Bioscience Corporation (NASDAQ:TWST) is one of the 10 Best Performing American Stocks in June 2026.

On July 6, 2026, Evercore ISI downgraded Twist Bioscience Corporation (NASDAQ:TWST) to In Line from Outperform with a price target of $102, up from $66. Evercore ISI said Twist has been one of the best performers in life science tools, up more than 200% year-to-date, with most of the move, or 85%, coming since its May 21 analyst day on optimism around AI-driven order momentum. The firm said it is taking some profits after the rally.

On June 29, Guggenheim raised the firm’s price target on Twist Bioscience to $107 from $60 and kept a Buy rating on the shares. Guggenheim adjusted models and forecasts for select companies in its diagnostics and life sciences tools coverage after meetings with management teams.

Evercore ISI Raises its Price Target on Twist Bioscience (TWST)

Pixabay/Public Domain

On June 24, Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience to $95 from $65 and kept an Overweight rating on the shares. Sergott adjusted targets in the life science and diagnostic tools space as part of a Q2 preview, noting that tools are “gaining favor among healthcare subsectors.” Barclays expects in-line to modest beats in Q2 for the group.

Twist Bioscience Corporation (NASDAQ:TWST) manufactures and sells synthetic DNA-based products.

While we acknowledge the risk and potential of TWST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TWST and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1